A combined approach for improving cardiopulmonary bypass in coronary artery surgery: a pilot study

Background: This is a pilot study carried out to assess the feasibility and the clinical impact of a combined approach of cardiopulmonary bypass (CPB) with reduced anti-coagulation. Methods: We used a retrospective, non-randomized analysis of 45 consecutive patients undergoing coronary artery bypass using standard CPB with full anticoagulation (activated clotting time, ACT, > 450 s) (Group 1; n = 23) or closed, heparin-coated CPB with low anticoagulation (ACT> 250 s), precise heparin and protamine titration, controlled suction, and retrograde autologous prime (Group 2; n = 22). Results: Patients were similar except for a higher incidence of three-vessel disease in Group 2 (77.3% versus 47.8%; p < 0.03). Heparin was reduced by 41% in Group 2 and protamine by 56% ( p < 0.0001). Total postoperative blood loss was similar between Groups 1 and 2 (429 ± 149 versus 435 ± 168 ml, respectively). However, the operative hematocrit decrease was lower in Group 2 (-1.6± 7.5% versus -6.9± 4.8%; p = 0.007), although hemodilution was similar, as reflected by the blood protein level. The need for postoperative inotropic support was less frequent in Group 2 (36.4% versus 65.2%; p = 0.05). Within the subgroup of patients weaned from CPB without requiring inotropic support ( n = 35), the cardiac index dropped significantly in Group 1 ( p = 0.003) 6 h after the start of CPB, whereas it remained stable in Group 2 ( p = 0.92). Using multivariate analyses, Group 2 was found to be more protected than Group 1 against myocardial cellular injury ( p = 0.046) and need for postoperative inotropic support ( p = 0.014). Conclusion: The pejorative postoperative outcome in coronary artery surgery was attenuated through a combined approach aimed at improving CPB.

[1]  I. Shapira,et al.  Protamine cardiotoxicity and nitric oxide. , 2001, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[2]  K. Kawazoe,et al.  Reduction of heparin dose is not beneficial to platelet function. , 2000, The Annals of thoracic surgery.

[3]  W. van Oeveren,et al.  Complement activation in coronary artery bypass grafting patients without cardiopulmonary bypass: the role of tissue injury by surgical incision. , 1999, Chest.

[4]  H. Kojima,et al.  Low-dose protamine based on heparin-protamine titration method reduces platelet dysfunction after cardiopulmonary bypass. , 1999, The Journal of thoracic and cardiovascular surgery.

[5]  R. Salamon,et al.  Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. , 1999, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[6]  W. van Oeveren,et al.  Procoagulant activity after off-pump coronary operation: is the current anticoagulation adequate? , 1999, The Annals of thoracic surgery.

[7]  L. Shore-lesserson,et al.  Pro: heparin-bonded circuits represent a desirable option for cardiopulmonary bypass. , 1998, Journal of cardiothoracic and vascular anesthesia.

[8]  C. B. Mahoney Heparin-bonded circuits: clinical outcomes and costs , 1998, Perfusion.

[9]  R. Shemin,et al.  Effect of anticoagulation protocol on outcome in patients undergoing CABG with heparin-bonded cardiopulmonary bypass circuits. , 1998, The Annals of thoracic surgery.

[10]  B. Vollmar,et al.  Enhancement of the leukocyte-endothelial cell interaction in collecting venules of skeletal muscle by protamine. , 1997, The Journal of thoracic and cardiovascular surgery.

[11]  D. Kuik,et al.  Clinical evaluation of Duraflo II heparin treated extracorporeal circulation circuits (2nd version). The European Working Group on heparin coated extracorporeal circulation circuits. , 1997, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[12]  S. Bannan,et al.  Low heparinization with heparin-bonded bypass circuits: is it a safe strategy? , 1997, The Annals of thoracic surgery.

[13]  C. Baufreton,et al.  Reduction of blood activation in patients receiving aprotinin during cardiopulmonary bypass for coronary artery surgery. , 1996, ASAIO journal.

[14]  H. O. Oudemans-van Straaten,et al.  Myocardial performance in elderly patients after cardiopulmonary bypass is suppressed by tumor necrosis factor. , 1995, The Journal of thoracic and cardiovascular surgery.

[15]  P. Bezemer,et al.  Reduced complement activation and improved postoperative performance after cardiopulmonary bypass with heparin-coated circuits. , 1995, The Journal of thoracic and cardiovascular surgery.

[16]  P. Everts,et al.  Systemic blood activation with open and closed venous reservoirs. , 1995, The Annals of thoracic surgery.

[17]  L. Greenfield,et al.  Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization. , 1994, The Journal of thoracic and cardiovascular surgery.

[18]  S. Westaby Aprotinin in perspective. , 1993, The Annals of thoracic surgery.

[19]  E. Blackstone,et al.  Effects of protamine administration after cardiopulmonary bypass on complement, blood elements, and the hemodynamic state. , 1986, The Annals of thoracic surgery.

[20]  C. Baufreton,et al.  Heparin coating with aprotinin reduces blood activation during coronary artery operations. , 1997, The Annals of thoracic surgery.

[21]  A. Galloway,et al.  Heparin bonding of bypass circuits reduces cytokine release during cardiopulmonary bypass. , 1995, The Annals of thoracic surgery.

[22]  Z. Fishelson,et al.  Synergism between zymosan-activated serum and heparin in the induction of polymorphonuclear leukocyte aggregation. , 1988, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.